Bradmer Pharmaceuticals Inc. (TSE:GLX – Free Report) – Investment analysts at Cantor Fitzgerald cut their FY2025 earnings per share estimates for shares of Bradmer Pharmaceuticals in a research note issued on Monday, March 31st. Cantor Fitzgerald analyst B. Knoblauch now expects that the company will post earnings of ($1.06) per share for the year, down from their previous forecast of $3.35. Cantor Fitzgerald currently has a “Strong-Buy” rating on the stock.
Bradmer Pharmaceuticals Price Performance
See Also
- Five stocks we like better than Bradmer Pharmaceuticals
- How to trade penny stocks: A step-by-step guide
- Homebuilders in Freefall: Bargain Opportunity or Falling Knife?
- How to Plot Fibonacci Price Inflection Levels
- The 3 Most Talked About Investments on WallStreetBets Right Now
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- Analyst Targets Signal More Growth in CrowdStrike Stock
Receive News & Ratings for Bradmer Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bradmer Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
